[앵커]
This year’s JP Morgan Healthcare Conference was attended by approximately 600 companies and 8,000 corporate investors. In particular, as a meeting can only be held with an official invitation from JP Morgan, the situation being discussed with the participating companies attracts attention.
Which domestic companies participated? Correspondent Hyosun Kim reports from the JP Morgan site in San Francisco, USA.
[기자]
On the 8th, local time in the United States, the 42nd JP Morgan Healthcare Conference began.
Among domestic companies, Samsung BioLogics and Celltrion present on the main track, showing the high status of K-Bio. Samsung BioLogics, invited to JP Morgan for the 8th consecutive year, explains its outlook for 2024 and its medium to long-term vision under the theme ‘Another leap beyond innovation’ on the 9th (the time of United States).
In particular, the company achieved rapid growth last year, surpassing 3 trillion won in cumulative orders despite difficult market conditions. At JP Morgan, Samsung BioLogics’ performance is being re-examined, and its 24-year portfolio is attracting attention.
In addition, ABL Bio, which reached a major agreement with Sanofi through JP Morgan in 2022, has a strategy to achieve results by expanding its business area through partnerships, not just technology transfer.
[이상훈/ 에이비엘바이오 대표]
“There are ongoing new partnerships this year. I think big pharma, now focused on M&A mergers rather than licensing, will return to introducing early candidate substances. So ABL is fully prepared for that and has been discussed with ongoing partners. “I believe that when the time is right, we will achieve great results.”
In addition, the company plans to share research results on solid cancer treatments such as ABL111 and ABL503 and seek a global partnership.
GI Innovation, invited to JP Morgan for three consecutive years, also actively promotes technology exchange and business cooperation.
[윤나리/ 지아이이노베이션 상무]
“It is clear that our company’s goal for this year is technology transfer. We are aiming for two major technology transfers. We are aiming for global technology transfer for immune anticancer drug GI-102. Metabolic immune anticancer drug GI- 108 will also be transferred within this year We are doing our best to make it happen.”
[김효선 기자]
This year, domestic pharma/bio companies are keen to participate in JP Morgan Healthcare. Among these companies, attention is focused on which one will be able to successfully open the door to a big deal this year. This is Kim Hyo-son from Pax Economy TV at the JP Morgan site in San Francisco.
[촬영·편집 = 장인식]
Copyright © Pax Economy TV Unauthorized reproduction and redistribution prohibited
#JPM #Focus #KBio #protagonists #years #big #deals #Samsung #BioLogics #ABL #Bio
